Corvus Pharmaceuticals In... (CRVS)
NASDAQ: CRVS
· Real-Time Price · USD
5.42
0.57 (11.75%)
At close: Aug 15, 2025, 3:59 PM
5.43
0.28%
After-hours: Aug 15, 2025, 07:49 PM EDT
Corvus Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -8M | 15.19M | -12.11M | -40.22M | -4.26M | -5.7M | -6.65M | -6M | -6.5M | -7.87M | -9.82M | -14.83M | -8.36M | -8.3M | -9.24M | -10.67M | -11.75M | -11.58M |
Depreciation & Amortization | 29K | 22K | 20K | 21K | 21K | 23K | 28K | 30K | 36K | 57K | 94K | 94K | 92K | 87K | 93K | 108K | 122K | 137K |
Stock-Based Compensation | 1.26M | 1.25M | 845K | 701K | 768K | 689K | 572K | 546K | 537K | 492K | 620K | 658K | 675K | 739K | 738K | 1.1M | 1.17M | 1.23M |
Other Working Capital | 1.07M | 1.43M | -2.16M | -299K | -140K | 135K | -497K | 75K | -1.44M | 410K | -543K | 2.81M | -373K | -807K | -42K | -172K | -682K | -207K |
Other Non-Cash Items | -1.96M | -24.88M | 4.24M | 32.85M | -1.46M | -387K | 1.8M | 620K | 1.03M | 1.47M | 4.43M | 4.47M | 1.64M | 1.1M | 2.59M | 1.75M | 537K | 195K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | -522K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 2.89M | 152K | -1.46M | 326K | -545K | 219K | -391K | -630K | -319K | -2.25M | -2.88M | 4.5M | -163K | -49K | -1.04M | -703K | -2.73M | 1.24M |
Operating Cash Flow | -5.78M | -8.26M | -8.46M | -6.32M | -5.48M | -5.16M | -5.17M | -5.43M | -5.22M | -8.11M | -7.55M | -6.93M | -6.12M | -6.42M | -6.86M | -8.43M | -12.65M | -8.79M |
Capital Expenditures | -113K | -36K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -34K | -4K | -265K | -4K | n/a | -5K | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | 4.64K | n/a | n/a | -4.64K | 22K | n/a | -3.14K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -39.48M | -7.71M | -20.36M | -18.84M | -26.29M | -4.63M | -11.43M | -1.81M | -20.72M | -13.09M | -19.3M | -17.47M | -3.04M | -26.38M | -4.49M | -154K | -1.39M | -3.32M |
Sales Maturities Of Investments | 19.29M | 11.99M | 14.27M | 14.95M | 8.79M | 4.62M | 9.11M | 19.36M | 16.43M | 17.73M | 15.4M | 20.77M | 6.18M | 810K | 2.5M | 3.63M | 16.63M | 8.17M |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | -4.64K | n/a | -4.29K | 4.64K | 4K | 3.31M | 3.14K | -25.57M | -1.99M | 3.47M | 15.24M | 4.85M |
Investing Cash Flow | -20.3M | 4.24M | -6.08M | -3.89M | -17.5M | -7K | -2.32M | 17.55M | -4.29M | 4.6M | -3.88M | 3.04M | 3.14M | -25.57M | -2M | 3.47M | 15.24M | 4.85M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 8K | 7.52M | 4K | n/a | n/a | n/a | n/a | 18K | 1.2M | n/a | n/a |
Financial Cash Flow | 35.77M | 279K | 18.61M | 50K | 30.37M | n/a | n/a | 335K | 7.52M | 4K | n/a | n/a | n/a | n/a | 18K | 18.33M | 11.22M | 32.59M |
Net Cash Flow | 9.69M | -3.74M | 4.06M | -10.16M | 7.38M | -5.16M | -7.49M | 12.45M | -2M | -3.5M | -11.43M | -3.89M | -2.98M | -32M | -8.84M | 13.38M | 13.81M | 28.65M |
Free Cash Flow | -5.89M | -8.3M | -8.46M | -6.32M | -5.48M | -5.16M | -5.17M | -5.43M | -5.22M | -8.14M | -7.55M | -7.19M | -6.13M | -6.42M | -6.86M | -8.43M | -12.65M | -8.79M |